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A broadly effective HIV-1 vaccine would greatly contribute towards pathway deepens our understanding of the level of somatic
prevention of the 2.1 million new HIV-1 infections estimated to occur
annually. Six HIV-1 vaccine efﬁcacy trials in humans have thus far been
conducted. Whereas most vaccines showed no efﬁcacy in preventing
from HIV-1 infection – and two actually increased infection rates in vac-
cine recipients – the RV144 Thai phase III HIV-1 vaccine trial is to date the
only one to have shown efﬁcacy, albeit marginally (31.2% decrease in
HIV-1 acquisition at 42 months post-vaccination) (reviewed in (Kim
et al., 2015)). Surely, this level of efﬁcacy is insufﬁcient; but these results
gave hope that correlates of protection could be identiﬁed and improved
upon as a path towards amore effective HIV-1 vaccine. In this issue, Nice-
ly et al. present atomic-level details of thematuration pathway taken by a
RV144 vaccine-induced antibody, CH58.
The regimen administered to RV144 Thai trial volunteers consisted of
four interspersed ALVAC™-HIV doses (canarypox-based viral vectorwith
env/gag/pol components) boosted twice with AIDSVAX® B/E (bivalent
monomeric gp120 protein) over six months (Rerks-Ngarm et al., 2009).
Rigorous efforts to uncover correlates of protection in vaccine recipients
revealed that IgG binding to a V1/V2 scaffold (HIV-1 gp120 variable
loops 1 and 2 displayed on the murine leukemia virus gp70 protein) in-
versely correlated with infection. Two isolated antibodies from vaccine
recipients, CH58 and CH59, bind to lysine 169 in gp120 V2 (Liao et al.,
2013), a position implicated by sieve analysis in blocking sequence-
matched HIV-1 strains. Interestingly, these antibodies only neutralize
HIV-1 weakly, but mediate effective antibody-dependent cell-mediated
cytotoxicity (ADCC) as the mechanism to thwart HIV-1.
Upon exposure to foreign antigens, precursor B cells undergo
afﬁnity-based selection and hypermutation of variable domains to gain
in afﬁnity and proliferate — a process termed afﬁnity maturation. To
shed light into the maturation pathway of the RV144 vaccine-induced
CH58 antibody, Nicely and colleagues inferred its precursor sequence,
and performed comparative structural and biophysical studies of the
germline antibody and its mature counterpart. Only 11mutations sepa-
rate the precursor sequence from the mature antibody — a maturation
pathway driven by the multivalent, prime-boost RV144 vaccine regi-
men. Conversely, the development of broadly neutralizing antibodies
(bnAbs) in naturalHIV-1 infection often requiresmore extensive afﬁnity
maturation. As an example, bnAb VRC01, which neutralizes ~90% of cir-
culating HIV-1 isolates, has 66 residue alterations encoded in its variable
light and heavy genes (Zhou et al., 2010). The CH58 afﬁnity maturationDOI of original article: http://dx.doi.org/10.1016/j.ebiom.2015.06.016.
http://dx.doi.org/10.1016/j.ebiom.2015.07.019
2352-3964/© 2015 The Author. Published by Elsevier B.V. This is an open access article underhypermutation achievable by current vaccination technology and serves
as a benchmark to evaluate whether re-elicitation of extensively mutat-
ed bnAbs like VRC01 might ever be feasible by vaccination.
Structural analysis of the predicted CH58 antibody precursor
by Nicely et al. reveals how the paratope is largely structurally pre-
conﬁgured for gp120 V2 recognition. The precursor light chain comple-
mentarity determining region 2 (LCDR2) already contains a Glu–Asp di-
peptide motif ideally positioned to recognize basic gp120 V2 residues.
Two of the 11 mutations acquired during somatic hypermutation con-
tribute two new salt bridges to V2 residues, and their role in the ob-
served gain in afﬁnity for mature CH58 (from 11.0 μM to 4.6 nM)
appears to be predominantly through decreasing off-rates (600-fold
decrease in off-rate, and 4-fold increase in on-rate).
The afﬁnity maturation pathway of CH58 described by Nicely and
colleagues is a clear example of the antibody precursor paratope being
largely pre-conﬁgured, and gaining in afﬁnity from few mutations
that improve off-rates. In that sense, the CH58-lineage resembles the
CH59-lineage (Wiehe et al., 2014), but differs from thematuration path-
way observed for some other antibodies. Indeed, conformational diversi-
ty, which is not evident in the CH58 precursor, had been previously
demonstrated to diversify the antibody germline repertoire and contrib-
ute towards molecular recognition of an increased number of antigens
when combined with sequence diversity (Wedemayer et al., 1997).
B cell ontogenies describe the evolution of antibody responses. In-
sights gained from such studies often guide immunogen design strate-
gies that seek to recapitulate or improve elicitation of speciﬁc B-cell
lineages in vaccination. For example, several bnAbs against the inﬂuen-
za hemagglutinin stem or against the HIV-1 Env receptor binding site
(RBS) have been shown to derive from the same germline precursor
genes — VH1-69 and VH1-2, respectively (reviewed in (Haynes et al.,
2012)). Re-eliciting these protective bnAb responses in vaccination is
a highly desirable goal. RecentHIV-1 immunogen-design efforts seeking
to target speciﬁc B-cell precursors in vaccination successfully initiated
the desired germline response (Dosenovic et al., 2015; Jardine et al.,
2015). However, germline-targeting might not always be the appro-
priate immunization strategy. The inherent diversity of the germline
repertoire can also result in convergence on immune solutions that
arise from different starting points, as recently described for bnAbs
against the inﬂuenza hemagglutinin RBS (Schmidt et al., 2015).
Will germline-targeting be a viable strategy to broaden the efﬁcacy
of anti-HIV-1 antibodies that mediate ADCC, such as those elicited inthe CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
633J.-P. Julien / EBioMedicine 2 (2015) 632–633the RV144 vaccine trial? Such questions can now be tackled in greater
depth based on a better understanding of the CH58 antibody-lineage
revealed by Nicely and colleagues.
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